This was in the comments from my blog post on Pfizer's semi-open innovation. I don't normally highlight comments like this, but sometimes you have to give credit where credit is due.
Why deal with Pfizer in the first place? Anything you might find they'll keep and you're SOL. We have a compound library that started from 1.4 million cmpds from Chemdiv, Chembridge, Maybridge and Tripos. I talked them into using our exclusion criteria (developed by my old buddies from Pharmacia - we all got Pfired when Pfizer took over Kazoo) and got rid of all the junk we didn't want (1 million). From there we used a "molecular equivalence" program to pick only unique compounds that we wanted to purchase - 100,000. I built my own library of off-patent FDA approved drugs (except opiods and benzo's). You can come to us with your screen and run it against our library of 10,00 (select set) or 100,000 full set and you get to keep whatever you find. No IP issues. Check us out.
This is why I love blogging. The writer is from the Michigan High Throughput Screening Center. And I think I've found a poster child for the Health Commons.
Medicine & Health
Life Science
Comments
There are a number of academic screening efforts and there is also the NIH Roadmap Molecular Libraries Production Center Network (MLPCN). Entry into the MLPCN is by peer reviewed application and the "cost" is that the data from the screen has to be deposited promptly in PubChem. Over 1100 assays have been entered into PubChem in the pilot phase and the production phase.
Posted by: DrZZ | May 21, 2009 5:22 AM